Overall, our data indicate that PABPN1 aggregation induces, in OPMD, both a gain of toxic function and a loss of physiological function and strongly support the application of a dual gene therapy approach as a novel treatment for OPMD in humans. The gene discussed is PABPN1; the disease is oculopharyngeal muscular dystrophy.